Kanker-actueel Diagnosis of colorectal cancer: IOBT - FOB tests - fecal occult blood test = immunochromatographic stool test, approved by FDA - is more sensitive, more reliable (100%), cheaper and less stressful for the patient to detect and identify

CANCER.

Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.

Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

Diagnosis of colorectal cancer: IOBT - FOB Test - immunochromatographic fecal occult blood test = stool test by FDA - is more sensitive, more reliable (100%), cheaper and less stressful for the patient in the screening and testing for colon cancer types, according to Yahoo two major studies and is recommended by the researchers as a standard procedure in the diagnosis of cancer types. Article posted September 2005

Experiences of cancer patients with complementary approaches, including psychosocial support, can be found in experience stories on our website and there are also some videos of cancer patients to see, click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary treatments for cancer. Then click on video.

September 16, 2005: Source: Pol Merkuriusz Lek. December 2004, 17 (102) :579-82 and WCOG 2005: Abstract 0527 DR. Presented Sept. 13, 2005.

A new immuunchromatografische fecal occult blood test (IOBT or FOB for short) (sorry dare the English description is not in Dutch translation, but it's a simple test of stool) is much more sensitive than the standard used blood test (GOBT) to detect of colon cancers and also better for detecting precursors of colorectal cancer, according to a 1 on 1 comparison in two large studies. A study was published in 2004 and now another large study recently shown to give the same results. The FDA has this test according to the author of the article from Medscape already approved for use. The Spanish investigator Dr. Enrique Quintero of the most recent study recommends following these study results as this test is now standard to use for everyone in the group's risk for getting a form of cancer.

Here a study quote literally translated from the most recent study:
The IOBT test was more sensitive and reliable than GOBT test, with a sensitivity of 50% for the detection and identification of advanced cancer of the type adeno, 100% for colorectal cancer and 58% for advanced neoplasia is malignant polyps confirmed by a colonoscopy . In comparison, the sensitivity of the test was GOBT 9% for detecting advanced colorectal adeno, 23% for colorectal cancer and 12% for advanced neoplasia confirmed by colonoscopy. This superior sensitivity was not obtained at the expense of specificity. Both tests had a specificity of 92% or more for the detection and identification of any of said conditions, confirmed by colonoscopy with IOBT test for 2 to 5% less than the specificity GOBT test. The Polish study abstract below, indicates highly significantly better results for the FOB test. We ask ourselves is whether all this test is performed in Dutch hospitals and whether this test could be an alternative to the general population for colorectal cancer which is now a lot of money is being spent to investigate whether this is desirable. IOBT the test is more sensitive, much cheaper and much less stressful for the patient. What more do we want. Successively the abstract of the study and Polish daronder Medscape article in the most recent Spanish study.

[Evaluation of faecal occult blood or Useful ness test. Prospective screening study in patient with colorectal neoplasia]

[Article in Polish]

Banaszkiewicz Z, Jawien A Jarmocik P Tojek K, M Jankowski, M. Switonski
Klinika Chirurgii Ogolnej Akademii Medycznej w Bydgoszczy. banaszkiewicz@mediclub.pl

High incidence of colorectal cancer (CRC), good treatment outcome in case of Surgery Performed at an early stage of the disease, and a simple, low cost and quick diagnostic test, the encouragement of common use for CRC screening. The Aim of the study was to Examine the Efficacy of immunochromatographic faecal occult blood (FOB) testing in screening for colorectal cancer early.

MATERIAL AND METHODS: A total of 346 subjects with abdominal symptoms or Unclear etiology Were included to the study. Patients diagnosed with CRC, or CRC Clinical Symptoms Suggesting Those with family history of CRC Were excluded from the study. All subjects would FOB testing done. All Were Subjected to sigmoidoscopy, no matter what the result of the screening test. The sensitivity and specificity of the screening test for CRC were Evaluated.

RESULTS: The total of 342 subjects aged 29-68 years (median 59 yrs), include 189 (58%) females and 153 (42%) males, Were Eventually qualified for the study. Colorectal pathology was found in 117 subjects (34.6%). Out of 62 patients with positive tests, 55 (89%) had a colorectal disorder diagnosed consistently sigmoidoscopy. Were the false positive results in 7 cases. Colorectal neoplasia was recognized in 33 cases. These Were Neoplastic polyps (23) and adenocarcinoma (10). The Great Majority of Neoplastic conditions Were found in FOB positive subjects. The sensitivity of the test was 90%, while specificity ITS Reached 84%. Diagnostic accuracy was 84%. Positive and negative predictive values Were 15% and 99% respectively.

CONCLUSIONS: FOB testing Appears highly sensitive and specific for colorectal cancer in patient with abdominal symptoms Unclear.

Publication Types:
Validation Studies

An article on this new diagnostic technique published in a recent study published Medscape nav:

PMID: 15771126 [PubMed - indexed for MEDLINE]
Immunochromatographic Test Superior to Gold Standard for Colorectal Cancer Screening

AlisonPalkhivala
Sept. 14, 2005 (Montreal) - A new immunochromatographic fecal occult blood test (IOBT) is far more sensitive Than the Standard Guaiac-based fecal blood test (GOBT) for detecting colorectal cancer as well as precancerous states, According To a head-to- head comparison.

"This immuno-chemical test Should Be Considered the first-choice test for fecal occult blood screening for colorectal cancer in the average-risk population," presenter Enrique Quintero, MD, Told Medscape. He is chief of the gastroenterology department at the Hospital Universitario des Canarias, La Laguna, Tenerife, Spain.

Dr. Quintero and colleagues compared the IOBT, Which was Developed in Japan and is called OC-Light, directly with the current standard GOBT (Hemo-Fec). Their goal was to Which qualification test must have the sensitivity and specificity for detecting colorectal cancer and precancerous states compared with colonoscopy. Hey Their Findings Presented in a poster here at the annual meeting of the World Congress of Gastroenterology.

"It's very easy to take a sample [Using the IOBT]," said Dr.. Quintero. "You collect the sample in a little bottle and put a strip inside. If you get one blue band, the test is negative, if you get a second belt [blue], that mean the test is positive." In Europe, the test costs about 3.00 Euros.

Between July 2003 and April 2005, the investigators Randomly selected 2650 Individuals aged 50 to 75 years from the Social Security Register of the Canary Islands for participation in the study. They excluded All Those with regular use of nonsteroidal anti-inflammatory drugs or anticoagulants, recent history of screening for colorectal cancer or digestive tract bleeding, and a family or personal history of colorectal cancer, inflammatory bowel disease, or coagulopathy. The Remaining Participants 2020, Considered to represent a population at average risk for colorectal cancer, Were asked to take the GOBT and IOBT and Were Also Invited to undergo a colonoscopy. Patiënten or thesis, 1559 (77%) completed Both fecal occult blood tests.

Overall, 8.4% of Patients IOBT had positive test results and 3.8% had positive test results GOBT. An Additional 1.9% of Patients On Both had positive tests results. Colonoscopy was Performed in 154 of the 161 patients who had positive results on tests and Either or thesis on 222 of the 1398 Patients who Were Both tests negative for.

Or The Patient with a positive fecal occult blood test, 26% Were found upon colonoscopy to have advanced adenomas, and 9% Were found to have colorectal cancer. In contrast, or patients with a negative fecal occult blood test, 2% had advanced adenomas, and colorectal cancer had none. Of the 14 patients with colorectal cancer, six had early-stage disease.

The test was far more sensitive IOBT Than GOBT the test with a sensitivity of 50% for the detection of advanced adenoma, 100% for colorectal cancer, and 58% for advanced neoplasia, compared with colonoscopy. In contrast, the sensitivity of GOBT was 9% for detection of advanced adenoma, 23% for colorectal cancer, and 12% for advanced neoplasia compared with colonoscopy. This superior sensitivity Obtained was not at the expense of specificity. Both tests had a specificity of 92% or more for the detection of Each of These conditions compared with colonoscopy, with IOBT 2% to 5% Less Than GOBT specify.

"And this was a study done with one-time screening," Dr. Quintero Told Medscape. "That if that mean everytime you repeat the test year or two, the sensitivity ... is going to be much higher."
The relative risk for advanced neoplasia in patient with positive results on a fecal occult blood test was 4.8 for the GOBT compared with 25.7 for the IOBT.
"We have to change our screening test for colorectal cancer," said Dr.. Quintero. He added thats the IOBT HAS leg Already approved by the Food and Drug Administration and is available in the U.S.

WCOG 2005: Abstract 0527 DR. Presented Sept. 13, 2005.

Reviewed by Gary D. Vogin, MD